I held OCC for some time, sold them and went to MSB, good choice...

First 30 Last

Share
Profile

Follow
kenjikool

13,326 Posts.

2809

02/01/25

19:00

Post #: 77250629
Share

Originally posted by Lucretious: ↑

Some Healthcare/biotechs on my list for 2025, with many already owned.

OCC - Orthocell -some big gains late in 2024, but outlook looks very promising going into 2025
CC5 - 2025 should see some continued orders of machines that will rerate the stock. I believe it likely Astra orders more but also that a nother one or two pharmas come on board
MEM - Low market cap, renewed management and better focus. Reproductive sector with device for humans, horses and cattle.
EIQ - traction being gained in heart sector - FDA approval likely in 2025
PCK - 2025 should bring FDA approval, children's app rollout and expansion in the UK.
RCE - a stock whose SP has been a dud for a while. But now grants from US DoD and Phase III trials in Indonesia for diabetic foot ulcers. Burns and UTI treatments are still there but on back burner as they try and get to commercial revenue with diabetic foot ulcer treatment.
BOT - treatment for profuse weating now on market after FDA approval
DXB - Lung health sector - making solid advances
PAR - after the mkt gets over the CR hangover, this should rise as it heads towards approvals

I would tip all of these to make in excess of 25% over the next 12 months. I will likely tip them throughout the year and try and pick the 8 week windows where they will do best !

Expand

I held OCC for some time, sold them and went to MSB, good choice overall, but would like to have been in both.
3 Upvote

0 Great analysis

Reply

Top Stories

Wednesday's HotCopper trends: DroneShield in Europe, Humm sale | June 25

ASX Market Close: Index flat as miners fall | June 25, 2025

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

DEL

Delorean to begin selling carbon offsets under regulation changes

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem